시장보고서

상품코드

1941426

자궁내막증 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료 유형별, 약제 클래스별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)

Endometriosis Treatment Market Size, Share & Trends Analysis Report By Treatment Type, Drug Class, Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033

발행일: 2026년 01월 | 리서치사:

Grand View Research | 페이지 정보: 영문 110 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

자궁내막증 치료 시장 요약

세계의 자궁내막증 치료 시장 규모는 2025년 19억 7,000만 달러로 추정되며, 2033년까지 46억 8,000만 달러에 이를 것으로 예측됩니다.

또한 2026-2033년 연평균 11.28% 성장할 것으로 예측됩니다. 증가하는 질병 부담, 질병에 대한 인식 개선, 탄탄한 제품 파이프라인이 시장 성장을 견인하는 주요 요인입니다.

세계보건기구(WHO)에 따르면, 전 세계 가임기 여성과 소녀의 약 10%가 자궁내막증을 앓고 있습니다. 미국 국립의학도서관이 2023년 2월에 보고한 바에 따르면, 인도에서만 약 4,200만 명의 여성이 이 질환의 영향을 받고 있는 것으로 추정됩니다. 이러한 놀라운 통계는 첨단 치료 솔루션의 시급한 필요성을 강조하고, 자궁내막증 치료 시장 기회가 확대되고 있음을 보여줍니다.

제약사들은 환자의 치료 성과 향상을 위한 새로운 치료법을 도입하여 증가하는 질병 부담에 적극적으로 대응하고 있습니다. 예를 들어, 지난 8월 화이자와 마이오밴트 사이언스는 폐경 전 여성의 자궁내막증에 따른 중등도에서 중증의 통증 완화를 위한 경구용 치료제 '마이펨브리(MYFEMBREE)'의 미국 FDA 승인을 받았다고 발표한 바 있습니다. 이번 성과는 이 질환을 앓고 있는 환자들의 미충족 수요를 충족시키는 데 있어 중요한 진전을 이룬 것으로 평가됩니다.

공중 보건 부문과 비영리 단체가 주최하는 인식 개선 캠페인도 중요한 역할을 하고 있습니다. 여성 건강에 대한 정부의 지원과 자궁내막증 치료에 대한 구체적인 가이드라인도 인지도 향상에 기여하고 있습니다. 예를 들어, 2022년 2월 유럽생식의학회(ESHRE)는 종합적인 진료 가이드라인을 발표했습니다. 이 가이드라인은 자궁내막증으로 인한 통증 완화 및 불임 대책을 포함한 질환 관리의 모범 사례로 치료 권장 사항과 진단 접근법을 제공합니다.

자주 묻는 질문

자궁내막증 치료 시장 규모는 어떻게 예측되나요?
- 2025년 19억 7,000만 달러, 2033년에는 46억 8,000만 달러에 이를 것으로 예측됩니다. 예측기간 동안 CAGR은 11.28%가 될 것으로 전망됩니다.
자궁내막증 환자의 수는 얼마나 되나요?
- 전 세계 가임기 여성과 소녀의 약 10%가 자궁내막증을 앓고 있으며, 인도에서는 약 4,200만 명의 여성이 이 질환의 영향을 받고 있는 것으로 추정됩니다.
자궁내막증 치료를 위한 최근의 주요 치료법은 무엇인가요?
- 화이자와 마이오밴트 사이언스는 폐경 전 여성의 자궁내막증에 따른 중등도에서 중증의 통증 완화를 위한 경구용 치료제 '마이펨브리(MYFEMBREE)'의 미국 FDA 승인을 받았습니다.
자궁내막증 치료에 대한 인식 개선을 위한 노력은 어떤 것이 있나요?
- 공중 보건 부문과 비영리 단체가 주최하는 인식 개선 캠페인과 정부의 지원, 자궁내막증 치료에 대한 구체적인 가이드라인이 인지도 향상에 기여하고 있습니다.
자궁내막증 치료에 대한 가이드라인은 어떤 내용을 포함하고 있나요?
- 2022년 2월 유럽생식의학회(ESHRE)는 자궁내막증으로 인한 통증 완화 및 불임 대책을 포함한 질환 관리의 모범 사례로 치료 권장 사항과 진단 접근법을 제공하는 종합적인 진료 가이드라인을 발표했습니다.

The global endometriosis treatment market size was estimated at USD 1.97 billion in 2025 and is projected to reach USD 4.68 billion by 2033, growing at a CAGR of 11.28% from 2026 to 2033. The rising disease burden, increasing disease awareness, and robust product pipeline are among the major factors driving the market growth.

According to the World Health Organization (WHO), approximately 10% of reproductive-age women and girls worldwide suffer from endometriosis. In India alone, the disorder affects an estimated 42 million women, as reported by the National Library of Medicine in February 2023. These alarming statistics underscore the urgent need for advanced therapeutic solutions, highlighting the growing market opportunity for endometriosis treatments.

Pharmaceutical companies are actively addressing this rising disease burden by introducing novel therapies aimed at improving patient outcomes. For instance, in August 2022, Pfizer Inc. and Myovant Sciences announced the U.S. FDA approval of MYFEMBREE, an oral treatment specifically designed to alleviate moderate to severe pain associated with endometriosis in premenopausal women. This development represents a significant step forward in addressing the unmet medical needs of patients suffering from this condition.

Awareness campaigns organized by public health departments and non-profit organizations also play a crucial role. Government support for women's health and specific guidelines for endometriosis care further contribute to heightened awareness. For example, in February 2022, the European Society of Human Reproduction and Embryology (ESHRE) published comprehensive guidelines on care. These guidelines provide best practices for managing the condition, including treatment recommendations and diagnostic approaches to alleviate pain and address infertility caused by endometriosis.

Global Endometriosis Treatment Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global endometriosis treatment market report on the basis of treatment type, drug class, route of administration, distribution channel, and region

Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
Pain Medication
Hormone Therapy
Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
NSAIDs
Oral Contraceptive
Gonadotropin Releasing Hormone
Others
Route Of Administration Outlook (Revenue, USD Million, 2021 - 2033)
Oral
Injectable
Others
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
Hospital Pharmacy
Retail Pharmacy
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- China
- Japan
- India
- Australia
- Thailand
- South Korea
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1 Methodology and Scope

1.1 Market Segmentation
- 1.1.1 Regional Scope
1.2 Market Definitions
- 1.2.1 Estimates And Forecast Timeline
1.3 Objectives
- 1.3.1 Objective - 1
- 1.3.2 Objective - 2
- 1.3.3 Objective - 3
1.4 Research Methodology
1.5 Information Procurement
- 1.5.1 Purchased Database
- 1.5.2 GVR's Internal Database
- 1.5.3 Secondary Sources
- 1.5.4 Primary Research
- 1.5.5 Details Of Primary Research
1.6 Information Or Data Analysis
- 1.6.1 Data Analysis Models
1.7 Market Formulation & Validation
1.8 Model Details
- 1.8.1 Commodity Flow Analysis
  - 1.8.1.1 Approach 1: Commodity Flow Approach
  - 1.8.1.2 Approach 2: Country Wise Market Estimation Using Bottom-up Approach
1.9 List Of Secondary Sources
1.10 List Of Abbreviations

Chapter 2 Executive Summary

2.1 Market Snapshot
2.2 Treatment Type And Drug Class Segment Snapshot
2.3 Route Of Administration And Distribution Channel Segment Snapshots
2.4 Competitive Landscape Snapshot

Chapter 3 Market Variables And Trends

3.1 Market Lineage Outlook
- 3.1.1 Parent Market Outlook
- 3.1.2 Related/ancillary Market Outloosk
3.2 Market Trends & Outlook
3.3 Market Dynamics
- 3.3.1 Market Driver Analysis
  - 3.3.1.1 Rising Disease Burden
  - 3.3.1.2 Growing Awareness Toward The Disease
  - 3.3.1.3 Increasing Funding For Research And Development
- 3.3.2 Market Restraint Analysis
  - 3.3.2.1 Availability Of Over The Counter And Generic Drugs
3.4 Business Environment Analysis
- 3.4.1 Porter's Five Forces Analysis
- 3.4.2 Pestel Analysis
3.5 Pipeline Analysis (Phase 3)

Chapter 4 Endometriosis Treatment Market- Segment Analysis, By Treatment Type, 2021 - 2033 (USD Million)

4.1 Endometriosis Treatment Market: Treatment Type Movement Analysis
4.2 Endometriosis Treatment Market Estimates & Forecast, By Treatment Type (USD Million)
- 4.2.1 Pain Medication
- 4.2.2 Hormone Therapy

Chapter 5 Endometriosis Treatment Market- Segment Analysis, By Drug Class, 2021 - 2033 (USD Million)

5.1 Endometriosis Treatment Market: Drug Class Movement Analysis
5.2 Endometriosis Treatment Market Estimates & Forecast, By Drug Class (USD Million)
- 5.2.1 Nsaids
- 5.2.2 Oral Contraceptives
- 5.2.3 Gonadotropin-releasing Hormone
- 5.2.4 Others

Chapter 6 Endometriosis Treatment Market- Segment Analysis, By Route Of Administration, 2021 - 2033 (USD Million)

6.1 Endometriosis Treatment Market: Route Of Administration Movement Analysis
6.2 Endometriosis Treatment Market Estimates & Forecast, By Route Of Administration (USD Million)
- 6.2.1 Oral
- 6.2.2 Injectable
- 6.2.3 Others

Chapter 7 Endometriosis Treatment Market- Segment Analysis, By Distribution Channel, 2021 - 2033 (USD Million)

7.1 Endometriosis Treatment Market: Distribution Channel Movement Analysis
7.2 Endometriosis Treatment Market Estimates & Forecast, By Distribution Channel (USD Million)
- 7.2.1 Hospital Pharmacies
- 7.2.2 Retail Pharmacies
- 7.2.3 Others

Chapter 8 Endometriosis Treatment Market: Regional Estimates And Trend Analysis By Type, Drug Class, Route Of Administration, And Distribution Channel

8.1 Endometriosis Treatment Market: Regional Outlook
8.2 North America
- 8.2.1 North America Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.2.2 U.S.
  - 8.2.2.1 Key Country Dynamics
  - 8.2.2.2 U.S. Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.2.2.3 Competitive/market Scenario
  - 8.2.2.4 Regulatory Framework
  - 8.2.2.5 Reimbursement Scenario
- 8.2.3 Canada
  - 8.2.3.1 Key Country Dynamics
  - 8.2.3.2 Canada Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.2.3.3 Competitive/market Scenario
  - 8.2.3.4 Regulatory Framework
  - 8.2.3.5 Reimbursement Scenario
- 8.2.4 Mexico
  - 8.2.4.1 Key Country Dynamics
  - 8.2.4.2 Mexico Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.2.4.3 Competitive/market Scenario
  - 8.2.4.4 Regulatory Framework
  - 8.2.4.5 Reimbursement Scenario
8.3 Europe
- 8.3.1 Europe Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.3.2 UK
  - 8.3.2.1 Key Country Dynamics
  - 8.3.2.2 UK Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.3.2.3 Competitive/market Scenario
  - 8.3.2.4 Regulatory Framework
  - 8.3.2.5 Reimbursement Scenario
- 8.3.3 Germany
  - 8.3.3.1 Key Country Dynamics
  - 8.3.3.2 Germany Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.3.3.3 Competitive/market Scenario
  - 8.3.3.4 Regulatory Framework
  - 8.3.3.5 Reimbursement Scenario
- 8.3.4 France
  - 8.3.4.1 Key Country Dynamics
  - 8.3.4.2 France Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.3.4.3 Competitive/market Scenario
  - 8.3.4.4 Regulatory Framework
  - 8.3.4.5 Reimbursement Scenario
- 8.3.5 Italy
  - 8.3.5.1 Key Country Dynamics
  - 8.3.5.2 Italy Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.3.5.3 Competitive/market Scenario
  - 8.3.5.4 Regulatory Framework
  - 8.3.5.5 Reimbursement Scenario
- 8.3.6 Spain
  - 8.3.6.1 Key Country Dynamics
  - 8.3.6.2 Spain Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.3.6.3 Competitive/market Scenario
  - 8.3.6.4 Regulatory Framework
  - 8.3.6.5 Reimbursement Scenario
- 8.3.7 Denmark
  - 8.3.7.1 Key Country Dynamics
  - 8.3.7.2 Denmark Influenza Vaccine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.3.7.3 Competitive/market Scenario
  - 8.3.7.4 Regulatory Framework
  - 8.3.7.5 Reimbursement Scenario
- 8.3.8 Sweden
  - 8.3.8.1 Key Country Dynamics
  - 8.3.8.2 Sweden Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.3.8.3 Competitive/market Scenario
  - 8.3.8.4 Regulatory Framework
  - 8.3.8.5 Reimbursement Scenario
- 8.3.9 Norway
  - 8.3.9.1 Key Country Dynamics
  - 8.3.9.2 Norway Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.3.9.3 Competitive/market Scenario
  - 8.3.9.4 Regulatory Framework
  - 8.3.9.5 Reimbursement Scenario
- 8.3.10 Rest Of Europe Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
8.4 Asia Pacific
- 8.4.1 Asia Pacific Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.4.2 Japan
  - 8.4.2.1 Key Country Dynamics
  - 8.4.2.2 Japan Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.4.2.3 Competitive/market Scenario
  - 8.4.2.4 Regulatory Framework
  - 8.4.2.5 Reimbursement Scenario
- 8.4.3 China
  - 8.4.3.1 Key Country Dynamics
  - 8.4.3.2 China Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.4.3.3 Competitive/market Scenario
  - 8.4.3.4 Regulatory Framework
  - 8.4.3.5 Reimbursement Scenario
- 8.4.4 India
  - 8.4.4.1 Key Country Dynamics
  - 8.4.4.2 India Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.4.4.3 Competitive/market Scenario
  - 8.4.4.4 Regulatory Framework
  - 8.4.4.5 Reimbursement Scenario
- 8.4.5 Australia
  - 8.4.5.1 Key Country Dynamics
  - 8.4.5.2 Australia Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.4.5.3 Competitive/market Scenario
  - 8.4.5.4 Regulatory Framework
  - 8.4.5.5 Reimbursement Scenario
- 8.4.6 Thailand
  - 8.4.6.1 Key Country Dynamics
  - 8.4.6.2 Thailand Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.4.6.3 Competitive/market Scenario
  - 8.4.6.4 Regulatory Framework
  - 8.4.6.5 Reimbursement Scenario
- 8.4.7 South Korea
  - 8.4.7.1 Key Country Dynamics
  - 8.4.7.2 South Korea Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.4.7.3 Competitive/market Scenario
  - 8.4.7.4 Regulatory Framework
  - 8.4.7.5 Reimbursement Scenario
- 8.4.8 Rest Of Asia Pacific Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
8.5 Latin America
- 8.5.1 Latin America Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.5.2 Brazil
  - 8.5.2.1 Key Country Dynamics
  - 8.5.2.2 Brazil Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.5.2.3 Competitive/market Scenario
  - 8.5.2.4 Regulatory Framework
  - 8.5.2.5 Reimbursement Scenario
- 8.5.3 Argentina
  - 8.5.3.1 Key Country Dynamics
  - 8.5.3.2 Argentina Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.5.3.3 Competitive/market Scenario
  - 8.5.3.4 Regulatory Framework
  - 8.5.3.5 Reimbursement Scenario
- 8.5.4 Rest Of Latin America Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
8.6 Middle East & Africa (Mea)
- 8.6.1 Mea Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.6.2 South Africa
  - 8.6.2.1 Key Country Dynamics
  - 8.6.2.2 South Africa Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.6.2.3 Competitive/market Scenario
  - 8.6.2.4 Regulatory Framework
  - 8.6.2.5 Reimbursement Scenario
- 8.6.3 Saudi Arabia
  - 8.6.3.1 Key Country Dynamics
  - 8.6.3.2 Saudi Arabia Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.6.3.3 Competitive/market Scenario
  - 8.6.3.4 Regulatory Framework
  - 8.6.3.5 Reimbursement Scenario
- 8.6.4 UAE
  - 8.6.4.1 Key Country Dynamics
  - 8.6.4.2 UAE Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.6.4.3 Competitive/market Scenario
  - 8.6.4.4 Regulatory Framework
  - 8.6.4.5 Reimbursement Scenario
- 8.6.5 Kuwait
  - 8.6.5.1 Key Country Dynamics
  - 8.6.5.2 Kuwait Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  - 8.6.5.3 Competitive/market Scenario
  - 8.6.5.4 Regulatory Framework
  - 8.6.5.5 Reimbursement Scenario
  - 8.6.5.6 Rest Of Mea Endometriosis Treatment Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 9 Competitive Landscape

9.1 Participant Categorization
9.2 Participants' Overviews
9.3 Financial Performance
9.4 Product Benchmarking
9.5 Company Market Position Analysis
9.6 Company Profiles
- 9.6.1 Bayer Ag
  - 9.6.1.1 Company Overview
  - 9.6.1.2 Financial Performance
  - 9.6.1.3 Product Benchmarking
  - 9.6.1.4 Strategic Initiatives
- 9.6.2 Pfizer, Inc
  - 9.6.2.1 Company Overview
  - 9.6.2.2 Financial Performance
  - 9.6.2.3 Product Benchmarking
  - 9.6.2.4 Strategic Initiatives
- 9.6.3 Abbvie, Inc
  - 9.6.3.1 Company Overview
  - 9.6.3.2 Financial Performance
  - 9.6.3.3 Product Benchmarking
  - 9.6.3.4 Strategic Initiatives
- 9.6.4 Astrazeneca
  - 9.6.4.1 Company Overview
  - 9.6.4.2 Financial Performance
  - 9.6.4.3 Product Benchmarking
  - 9.6.4.4 Strategic Initiatives
- 9.6.5 Obseva Sa
  - 9.6.5.1 Company Overview
  - 9.6.5.2 Financial Performance
  - 9.6.5.3 Product Benchmarking
  - 9.6.5.4 Strategic Initiatives
- 9.6.6 Teva Pharmaceutical Industries
  - 9.6.6.1 Company Overview
  - 9.6.6.2 Financial Performance
  - 9.6.6.3 Product Benchmarking
  - 9.6.6.4 Strategic Initiatives
- 9.6.7 Zydus Healthcare Limited
  - 9.6.7.1 Company Overview
  - 9.6.7.2 Financial Performance
  - 9.6.7.3 Product Benchmarking
  - 9.6.7.4 Strategic Initiatives
- 9.6.8 Astellas Pharma, Inc.
  - 9.6.8.1 Company Overview
  - 9.6.8.2 Financial Performance
  - 9.6.8.3 Product Benchmarking
  - 9.6.8.4 Strategic Initiatives
- 9.6.9 Gedeon Richter Plc.
  - 9.6.9.1 Company Overview
  - 9.6.9.2 Financial Performance
  - 9.6.9.3 Product Benchmarking
  - 9.6.9.4 Strategic Initiatives
- 9.6.10 Takeda Pharmaceutical Company Limited
  - 9.6.10.1 Company Overview
  - 9.6.10.2 Financial Performance
  - 9.6.10.3 Product Benchmarking
  - 9.6.10.4 Strategic Initiatives
9.7 Strategy Mapping
- 9.7.1 New Product Launches
- 9.7.2 Acquisition
- 9.7.3 Collaborations
- 9.7.4 Partnerships
- 9.7.5 Others (Clinical Trials, Campaign, Legal, And Pricing)

자궁내막증 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료 유형별, 약제 클래스별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)

Endometriosis Treatment Market Size, Share & Trends Analysis Report By Treatment Type, Drug Class, Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033

자궁내막증 치료 시장 요약

자주 묻는 질문

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수와 동향

제4장 자궁내막증 치료 시장 - 부문 분석 : 치료 유형별, 2021년-2033년

제5장 자궁내막증 치료 시장 - 부문 분석 : 약제 클래스별, 2021년-2033년

제6장 자궁내막증 치료 시장 - 부문 분석 : 투여 경로별, 2021년-2033년

제7장 자궁내막증 치료 시장 - 부문 분석 : 유통 채널별, 2021년-2033년

제8장 자궁내막증 치료 시장 : 지역별 추정 및 동향 분석(유형별, 약제 클래스별, 투여 경로별, 유통 채널별)

제9장 경쟁 구도

제10장 결론

Endometriosis Treatment Market Summary

Table of Contents